Shire PLC (LON:SHP)‘s stock had its “overweight” rating reissued by investment analysts at JPMorgan Chase & Co. in a research note issued to investors on Monday.

Other equities analysts also recently issued research reports about the stock. HSBC lowered their price target on shares of Shire PLC from GBX 5,250 ($65.59) to GBX 5,200 ($64.97) and set a ” hold” rating on the stock in a report on Wednesday, September 28th. Shore Capital reissued a “buy” rating on shares of Shire PLC in a report on Friday, July 22nd. Liberum Capital reissued a “buy” rating and issued a GBX 5,500 ($68.72) target price on shares of Shire PLC in a report on Friday, July 29th. Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a report on Wednesday, August 3rd. Finally, Deutsche Bank AG reissued a “buy” rating and issued a GBX 6,000 ($74.96) target price on shares of Shire PLC in a report on Wednesday, August 3rd. One analyst has rated the stock with a sell rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Shire PLC has a consensus rating of “Buy” and a consensus target price of GBX 5,992.27 ($74.87).

Analyst Recommendations for Shire PLC (LON:SHP)

Shire PLC (LON:SHP) opened at 4852.50 on Monday. The company’s market cap is GBX 43.68 billion. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00. The company’s 50 day moving average is GBX 4,957.26 and its 200 day moving average is GBX 4,707.98.

In related news, insider Dominic Blakemore purchased 133 shares of the business’s stock in a transaction dated Friday, September 30th. The shares were purchased at an average cost of GBX 5,010 ($62.59) per share, for a total transaction of £6,663.30 ($8,324.96).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.